1. Home
  2. TCBS vs CALC Comparison

TCBS vs CALC Comparison

Compare TCBS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Texas Community Bancshares Inc.

TCBS

Texas Community Bancshares Inc.

HOLD

Current Price

$16.65

Market Cap

48.6M

Sector

Finance

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.59

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCBS
CALC
Founded
1934
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.6M
88.3M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
TCBS
CALC
Price
$16.65
$0.59
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
2.0K
559.2K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
1.20%
N/A
EPS Growth
N/A
N/A
EPS
0.69
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$24.13
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.01
$0.46
52 Week High
$20.00
$7.20

Technical Indicators

Market Signals
Indicator
TCBS
CALC
Relative Strength Index (RSI) 47.37 25.30
Support Level $15.69 $0.51
Resistance Level $16.69 $0.79
Average True Range (ATR) 0.27 0.07
MACD -0.03 0.17
Stochastic Oscillator 17.11 53.29

Price Performance

Historical Comparison
TCBS
CALC

About TCBS Texas Community Bancshares Inc.

Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: